Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

Phase 2 Terminated 8 enrolled Revimmune Washington University School of Medicine · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A prospective, single-center, single-blinded study involving patients with refractory nontuberculous mycobacteria lung disease to ascertain pharmacokinetics, safety, efficacy, and tolerability of two dose levels of parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107).

Timeline

Start: 2020-11-30
Primary completion: 2023-12-31
Completion: 2024-03-30

Outcome

Missed primary endpoint

Stopped: “non convincing results”

paper yet none converted their sputum culture to negative at 6 months. PMID 40351870 ↗

Publications

Mejia-Chew C, Spec A, Walton AH, Ulezko Antonova A, Dram A, Bhalla S, Colonna M, Morre M, Hotchkiss R. Recombinant interleukin-7 treatment of refractory Mycobacterium avium complex lung disease (IMPULSE-7): a pilot phase II, single-center, randomized, clinical trial. Ther Adv Infect Dis. 2025 May 10;12:20499361251339300. doi: 10.1177/20499361251339300. eCollection 2025 Jan-Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Interleukin-7	Protein / enzyme biologic	10 ug/kg	Intramuscular
Subject	Interleukin-7	Protein / enzyme biologic	20 ug/kg	Intramuscular